Islander
06-16-11, 10:54 AM
By Julie Steenhuysen (http://blogs.reuters.com/search/journalist.php?edition=us&n=julie.steenhuysen&)
CHICAGO | Wed Jun 15, 2011
(Reuters) - A mist inhaler used to improve breathing in people with lung diseases including chronic bronchitis and emphysema may increase their risk of dying by 52 percent, U.S. and British researchers said on Tuesday.
The increased risk occurred in patients who used the Spiriva Respimat inhaler, a newer device sold by privately held Boehringer Ingelheim (BI) and Pfizer. It delivers a soluble form of Spiriva, known generically as tiotropium.
The finding was contested by Pfizer and BI.
The inhaler is used to treat chronic obstructive pulmonary disease, or COPD, the fourth-leading cause of death worldwide, which includes the chronic lung diseases emphysema and bronchitis. COPD is usually due to decades of smoking.
Read more: http://www.reuters.com/article/2011/06/15/us-inhaler-deaths-idUSTRE75D6YC20110615?feedType=nl&feedName=ushealth1100
CHICAGO | Wed Jun 15, 2011
(Reuters) - A mist inhaler used to improve breathing in people with lung diseases including chronic bronchitis and emphysema may increase their risk of dying by 52 percent, U.S. and British researchers said on Tuesday.
The increased risk occurred in patients who used the Spiriva Respimat inhaler, a newer device sold by privately held Boehringer Ingelheim (BI) and Pfizer. It delivers a soluble form of Spiriva, known generically as tiotropium.
The finding was contested by Pfizer and BI.
The inhaler is used to treat chronic obstructive pulmonary disease, or COPD, the fourth-leading cause of death worldwide, which includes the chronic lung diseases emphysema and bronchitis. COPD is usually due to decades of smoking.
Read more: http://www.reuters.com/article/2011/06/15/us-inhaler-deaths-idUSTRE75D6YC20110615?feedType=nl&feedName=ushealth1100